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image-guided radiation therapy could improve the treatment accuracy 
of high precision stereotactic radiosurgery.
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Background: The prognosis of patients with NSCLC is still poor. 
Amongst distant metastases, also local tumour recurrence is still a 
problem. Because charged particles (protons and C-ions) have a bet-
ter dose-distribution than the currently used photons, at least from a 
theoretical point of view, they should lead to superior results compared 
to photons. On top of the physical superiority of protons over photons, 
C-ions also display a biological advantage.
Aim: In this review, we searched for clinical evidence that protons or 
C-ions would really be beneﬁcial to patients with NSCLC.
Methods: We performed a review based on published literature by 
means of a standardized query using the following electronic databases 
(up until January 31, 2007): CINAHL, EMBASE and MEDLINE. 
There was no limit applied to publication year, language or study 
design. Search terms (using free text words as well as MESH terms) 
were used alone or in combination, related to lung cancer and charged 
particle treatment. This included the following terms: neoplasm, cancer, 
carcinoma, lung cancer, proton, ion, charged particle and hadron. 
Results: Six fully published series (protons:3, C-ions:3), all dealing 
with NSCLC, mainly stage I, were identiﬁed. No phase III trials could 
be identiﬁed. On proton therapy, weighted means of 2-5 year local 
tumour control rates varied between 68% and 84%. The weighted 
mean for 2 year/5 year overall survival and 2 year/5 year cause speciﬁc 
survival were 53%/23% and 66%/46% respectively. Radiation induced 
pneumonitis was observed in about 10% of the patients. On C-ion 
therapy, the local tumour control rate was 77% and the 5 year overall 
survival and cause speciﬁc survival rates were 42% and 60% respec-
tively.
Conclusion: The results with charged particles, at least for stage I 
disease, seem to be better than that which is generally achieved by con-
ventional radiotherapy. However, they seem to be similar to what may 
be achieved with hypofractionated “stereotactic” photon techniques, 
with which in several phase I/II studies, local tumour control rates of 
90 % and more were reported. Due to the overwhelming theoretical 
data on the beneﬁcial properties of protons and light ions, further in-
vestment in the infrastructure needed to perform large trials in patients 
with different lung cancer stages, is warranted.
Until these results are available, for lung cancer, charged particle 
therapy should be considered as experimental. 
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Background: Radiotherapy of tumors in the lung is often limited by 
the relatively low dose tolerance of the lung. One method to reduce the 
toxicity of these treatments is to reduce the volume of lung irradiated 
by using image guided setup and/or gating. The current generation of 
medical linear accelerators have both kVp imaging and gating, allow-
ing the implementation of image guided gated radiotherapy. Tumors, 
however, are often not evident on kVp projection images, but this 
limitation can be overcome by the use of implanted ﬁducials.
Methods: A patient was broncoscopically implanted with 4 ﬁducials. 
All but one was lost within the ﬁrst few days after implantation, and the 
last one remained for the entire treatment. On each day the patient was 
imaged using the kVp on-board imager. The imager was triggered with 
the same respiratory gating system used to the gate the treatment. The 
ﬁducial was used to align the patient; if a shift was made a 2nd set of 
kVp images was taken to validate the shift. The ﬁducial was aligned us-
ing both a point matching tool (ISOLOC, CIVCO, Kalona, IA) and an 
image overlay tool (4DTC, Varian, Palo Alto, CA). We also validated 
the setup by examining the projection of the ﬁducial on cine images 
acquired during the delivery of one the treatment ﬁelds.
Results: We were able to analyze shift data from 24 of 30 treatment 
days. The values of the initial shifts were -1.4±1.9, 5.3±2.2 and 0.5±2.2 
mm in the lateral, cranial-caudal, and AP directions, respectively. The 
values of the residual error after the initial shifts calculated from the 
2nd set of kVp images were -0.4±1.4, -0.6±3.5 and -0.6±1.3 mm in 
each direction. The point matching and image overlay systems were 
consistent at the 1 mm level. The cine images were taken in the AP di-
rection and data could only be extracted for the lateral and cranial-cau-
dal directions. These results were 0.1 ± 1.1 and 1.1 ± 2.2 mm respec-
tively. These data suggest that the uncertainty in the gating represented 
about 4 mm of tumor motion. 
Conclusion: Fiducial-based setup of lung patients using either a point-
based or image-based system is practical using existing commercially 
available tools. Gating, however only reduces and does not completely 
eliminate tumor motion. An internal margin (IM) must therefore be 
included in the treatment plan to account for the uncertainty in the 
gated motion. 
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Purpose: Synchrony, the respiratory tracking system of the CyberKnife 
requires the insertion of markers in or close to the tumor. However, in 
this group of inoperable patients, it is associated with high risks like 
pneumothorax. To reduce the risks, 4 different methods of marker 
placement were used: 1) intravascular coil placement, 2) percutaneous 
intrapulmonal, 3) percutaneous extrapulmonal placement (for ﬁxed 
tumors to the thorax), and 4) the bronchoscopic placement. To evaluate 
these techniques, we investigated the toxicity of the marker place-
ment and the tumor response of the treatment. Until now 70 tumors are 
treated, but because the follow up is too short, we report the results of 
the ﬁrst 55 patients with 60 tumors.
Methods and Materials: Markers were placed in or around 60 tumors 
in 55 patients. Forty eight patients were treated with curative intention: 
40 patients had a T1-3N0M0 lung cancer and 8 patients had 13 solitary 
metastases in the lung. Seven patients were treated with palliative 
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intention (5 with recurrent lung cancer, and 2 with metastasis from lung 
cancer). Platinum ﬁducials and intravascular embolisation coils were 
used as markers. In total, 180 markers were placed: 67 intrapulmonal 
in 26 patients (median: 3 markers per tumor), 84 intravascular in 28 
patients (median: 3 makers per tumor), 25 extrapulmonal in 5 patients 
(median: 5 makers per tumor), and 4 markers in 1 patient with the 
bronchoscopic method. Seven days after marker placement, a planning 
CTscan was made and the GTV was contoured on a 4-D CT scan. The 
PTV equaled the GTV plus 5 mm. For early stage lung cancer, a total 
dose of 36 to 60 Gy, (median dose: 60 Gy) was given in 3 fractions. 
Solitary metastasis to the lung were treated with a total dose of 45 to 60 
Gy (median dose: 45 Gy) in 3 to 5 fractions. For palliative treatment, a 
total dose of 30 to 49 Gy was given in 3-7 fractions (median dose: 40 
Gy). The dose to the PTV was prescribed to the 70-85% isodose line. 
The response was evaluated according to the RECIST criteria with a 
CT scan 6-8 weeks after the last treatment and routinely thereafter. The 
median follow up with CTscan was 6 months (range: 2-18).
Results: Six patients (11%) had a pneumothorax after intrapulmonal 
placement. One patient had no symptoms. A thorax drain was placed 
in the 5 other patients. One patient complained of severe intrathora-
cal pain several hours after intravascular coil placement and 5 patients 
complained of haemoptoe, one after the intravascular coil placement 
and 4 after the intrapulmonal placement.
The local control was 97%. Seven tumors had a complete response, 
38 tumors had a partial response, 13 tumors had stable disease and 2 
tumors (both early stage lung cancer) were progressive, one after 8 
months and the other after 15 months. 
Conclusion: Low toxicity of marker placement was seen due to the 
4 methods. CyberKnife tumor tracking with markers is feasible and 
resulted in excellent tumor response.
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Background: Local recurrence is a major problem after (chemo-)ra-
diation for NSCLC. We hypothesized that for each individual patient 
the highest therapeutic ratio could be achieved by increasing the total 
tumor dose (TTD) to the limits of the normal tissues, delivered within 
5 weeks. In a theoretical model this resulted in an increase in tumor 
control probability from approximately 5% for a classical scheme (60 
Gy in 6 weeks) to 25% for the study scheme. Here, we report the ﬁrst 
results of a prospective clinical trial.
Methods: Twenty-nine patients with medically inoperable (stage I, 
n=2) or locally advanced NSCLC (stage III, n=27), in a good general 
condition (WHO-PS 0-1) and with a reasonable lung function (FEV1 
>50% of predicted) were included. Most patients (25/29) received 
induction chemotherapy. All patients were irradiated using an individu-
alized prescribed TTD, based on normal tissue constraints (mean lung 
dose 19 Gy, maximal spinal cord dose 54 Gy, no constraints for esopha-
gus) up to a maximal TTD of 79.2 Gy. Radiotherapy was delivered in 
1.8 Gy fractions, twice daily. Acute and late (>3 months) toxicity was 
scored using the CTCAE-criteria. A FDG-PET-CT scan (n=27) was 
performed to evaluate (metabolic) response 70 days after radiotherapy 
according to EORTC-criteria (PET) and RECIST-criteria (CT). The 
Kaplan-Meier method was used to compute overall survival. 
Results: The mean delivered dose was 62.7 Gy (range 46.8-79.2 Gy). 
This corresponds to a mean biological equivalent dose of approxi-
mately 80 Gy (2 Gy fractions, once daily, in 8 weeks). Most patients 
experienced mild acute toxicity, while only 2 patients (6.8%) developed 
acute grade 3 toxicity (n=1 dysphagia, n=1 cough) as depicted in ﬁgure 
1. Concerning late toxicity, 93% of patients (n=25) showed radiograph-
ic changes (75% in <25% and 18% in >25% of the lungs), while 12 out 
of 28 patients (43%) had clinical symptoms (>gr 1 pneumonitis). One 
patient (3.4%) died 51 days after radiotherapy due pneumonitis (treat-
ment related mortality). 
The post-radiotherapy PET-CT showed in 18 patients a metabolic 
response (41% complete metabolic response, 26% partial metabolic 
response), whereas only in 9 patients (33.3%) a response was seen 
on CT (p=0.01). Eight patients (29.6%) showed progressive disease, 
consisting of loco-regional progression (n=4), metastases (n=3) or a 
combination of both (n=1). With a mean FU of 13 months the mean 
overall survival was 16.7 months and a 1-yr survival of 65%.
Conclusions: Personalized HI-CHART radiation prescription based on 
normal tissue constraints is tolerable and initial results are promising.
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